MusclePharm Announces Key Executive Appointments
April 14 2014 - 8:00AM
Marketwired
MusclePharm Announces Key Executive Appointments
Donald Prosser Appointed Chief Financial Officer; Richard
Estalella Promoted to President
DENVER, CO--(Marketwired - Apr 14, 2014) - MusclePharm
Corporation (OTCQB: MSLP), a leading international, award-winning
sports nutrition company, today announced the appointment of Donald
W. Prosser as Chief Financial Officer and the promotion of Richard
Estalella to President, in addition to his role as Chief Operating
Officer.
Concurrent with Prosser's appointment, he has resigned his
position as an independent member of MusclePharm's Board of
Directors. Concurrent with Estalella's promotion, Brad Pyatt,
Chairman and CEO of MusclePharm resigned his position as President
of the Company. Gary Davis, the former CFO of MusclePharm, will
continue to serve the Company in an advisory capacity on special
projects through 2014. The management changes and promotion were
approved by MusclePharm's Board on April 10, 2014 and will become
effective April 16, 2014.
"Don brings vast experience in finance, accounting and corporate
governance, and we believe that he will be instrumental in the
planning and management of MusclePharm's financial strategy as we
continue our strong growth trajectory," said Brad Pyatt, Chairman
and CEO of MusclePharm.
"I would also like to acknowledge Richard's outstanding
contribution since joining us nearly a year ago, helping us
optimize the company's supply chain, distribution and warehouse
operations, and laying the groundwork for profitable expansion
domestically and throughout the world. His experience and
leadership will be important as we move into new markets and
introduce new products and product extensions," Pyatt said.
Following is biographical information on Prosser:
Donald W. Prosser
Prosser is a practicing certified public accountant,
specializing in tax and securities accounting, and has represented
a number of companies serving in the capacity of CPA, member of
boards of directors, and as Chief Financial Officer. He served as
an independent director on MusclePharm's board since July 2012 and
has more than 35 years of finance and accounting experience.
Prosser has served as Chief Financial Officer and Director of
Chartwell International, Arête Industries, Inc., Inform Worldwide
Holdings, VCG Holding Corp, among other companies.
About MusclePharm MusclePharm® is a scientifically-driven,
performance lifestyle Company that currently develops,
manufactures, markets and distributes branded nutritional
supplements. We offer a complete range of powders, capsules,
tablets and gels. Our portfolio of recognized brands, including
MusclePharm® Hybrid and Core Series, Arnold Schwarzenegger Series™
and FitMiss™, are marketed and sold in more than 110 countries and
available in over 35,000 retail outlets globally. These
clinically-proven and scientific nutritional supplements are
developed through a six-stage research process utilizing the
expertise of leading nutritional scientists, doctors and
universities. We are the innovator of the sports nutrition
industry. For more information, visit www.musclepharm.com.
Follow the company at http://www.facebook.com/MusclePharm and
www.Twitter.com/MusclePharm
To sign up to receive MusclePharm news via email, please visit
http://ir.musclepharmcorp.com/email-alerts
Forward-Looking Statements This release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities and Exchange
Act of 1934, as amended. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. Actual results may differ materially from
those set forth in this release due to the risks and uncertainties
inherent in the Company's business. More detailed information about
the Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2012,
the Company's Quarter Reports on Form 10-Q and other filings
submitted by the Company to the SEC, copies of which may be
obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and the Company undertakes no obligation to
revise or update this release to reflect events or circumstances
after the date hereof
Contacts: Matt Sheldon/Evan Pondel PondelWilkinson Inc. (310)
279-5980 Email Contact